Login
$AVBP
$11.56 +$0.00 (0.0%) After hours

$AVBP SEC Filings

Filed On Filing
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC

05 Nov 2026 SCHEDULE 13G/A
02 Nov 2026 Form 4: LaChapelle Robin, Chief Operating Officer

Received 40,693 shares by exercise or conversion ($185K)

26 Oct 2026 8-K: Regulation FD Disclosure; Other Events

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

19 Oct 2026 8-K: Regulation FD Disclosure

NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic...

13 Oct 2026 SCHEDULE 13G
13 Oct 2026 8-K: Regulation FD Disclosure; Other Events

NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic...

08 Oct 2026 SCHEDULE 13D/A
06 Oct 2026 8-K: Regulation FD Disclosure; Other Events

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

12 Aug 2026 10-Q
12 Aug 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026

27 Jul 2026 SCHEDULE 13G/A
22 Jun 2026 Form 4: Parsey Merdad, Director

Granted 13,562 Non-Qualified Stock Option (right to buy)

22 Jun 2026 Form 4: Peterson Kristine, Director

Granted 13,562 Non-Qualified Stock Option (right to buy)

22 Jun 2026 Form 4: Hohneker John, Director

Granted 13,562 Non-Qualified Stock Option (right to buy)

22 Jun 2026 Form 4: Nolet Chris, Director

Granted 13,562 Non-Qualified Stock Option (right to buy)

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2026, ArriVent BioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 46,368,442 shares of common stock, par value $0.0001 per share,...

11 May 2026 8-K: Other Events

We have acted as counsel to ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), with respect to certain matters in connection with the Automatic Shelf Registration Statement on Form S-3ASR (File No. 333-284661) (the “Regist...

11 May 2026 424B5

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support